Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
Answer from: Radiation Oncologist at Community Practice
No. Osimertinib alone is a palliative treatment with limited durability, which is not appropriate as first-line therapy for a patient who is interested in and eligible for definitive treatment. While the outcomes of the control arm of chemoradiotherapy without osimertinib in the LAURA trial were cer...
Comments
Medical Oncologist at Henry Ford Cancer Institute/Henry Ford Hospital Agree. However, the question is whether starting w...
Agree. However, the question is whether starting w...